title: Pertuzumab for the treatment of breast cancer: a safety review.
abstract: BACKGROUND
  Approximately twenty to thirty percent of newly diagnosed breast cancers are human epidermal growth factor receptor 2 (HER2) positive. The use of trastuzumab, and more recently pertuzumab, has significantly improved the progression free survival (PFS) and overall survival (OS) in this patient population. However, pertuzumab has side effects that can impact treatment tolerability and quality of life.
  
  
  METHODS
  This review describes the safety and tolerability of pertuzumab, a monoclonal antibody targeted at HER2 approved by the United States Food and Drug Administration (FDA) for use in the neoadjuvant and first line metastatic settings.
  
  
  CONCLUSIONS
  The combination of trastuzumab, pertuzumab, and chemotherapy is approved in the neoadjuvant and first line metastatic settings and should be strongly considered by providers. Further studies are needed to look at side effect prevention, novel pertuzumab containing regimens, and re-treating patients with pertuzumab.
authors.affiliation: a Department of Medical Oncology Service , National Cancer Institute, National Institutes of Health (NIH) , Bethesda , MD , USA.
authors.forename: Jennifer
authors.initials: J
authors.lastname: Gao
authors.affiliation: b Washington Cancer Institute, MedStar Washington Hospital Center , Washington , DC , USA.
authors.forename: Sandra M
authors.initials: SM
authors.lastname: Swain
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D011788:Quality of Life; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D015996:Survival Rate
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D018719:Erb-b2 Receptor Tyrosine Kinases; C508053:ERBB2 protein, human; C485206:pertuzumab
keywords: CLEOPATRA; HER2; NeoSphere; Pertuzumab; TRYPHAENA; monoclonal antibody; trastuzumab